Payal Banerjee

All stories by Payal Banerjee

Govt to repurpose CoWIN to include all vaccination

Govt to repurpose CoWIN to include all vaccination

Rediff.com1 days ago

The Universal Immunisation Programme is one of the largest vaccination projects in the world aimed at protecting children and pregnant mothers from preventable diseases. Under it, the government provides shots for 12 vaccine-preventable diseases, such as polio, diphtheria, tetanus, measles, and hepatitis B, for free.

Monkeypox outbreak: Govt alerts agencies, asks them to keep vigil

Monkeypox outbreak: Govt alerts agencies, asks them to keep vigil

Rediff.com7 days ago

The Union health ministry has also directed airport and port health officers to be vigilant, they said.

India likely to reduce Covid booster gap to 6 months, decision on Friday

India likely to reduce Covid booster gap to 6 months, decision on Friday

Rediff.com27 Apr 2022

The government is likely to soon reduce the gap between the second dose of Covid-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday.

Future Covid waves unlikely to have serious impact in India: Experts

Future Covid waves unlikely to have serious impact in India: Experts

Rediff.com20 Mar 2022

The reason is that because of the hybrid immunity after three waves of natural infection and a large proportion of adults receiving both doses of COVID-19 vaccine, the susceptible pool has come down drastically, Lahariya said.

Covishield, Covaxin get regular market approval

Covishield, Covaxin get regular market approval

Rediff.com27 Jan 2022

Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting.Adverse event following immunisation will continue to be monitored.

Govt panel recommends regular market approval for Covishield, Covaxin

Govt panel recommends regular market approval for Covishield, Covaxin

Rediff.com20 Jan 2022

An expert panel of India's central drug authority on Wednesday recommended granting regular market approval to COVID vaccines Covishield and Covaxin for use in adult population subject to certain conditions, official sources said.

Molnupiravir not to be included in Covid treatment now

Molnupiravir not to be included in Covid treatment now

Rediff.com11 Jan 2022

The Indian Council of Medical Research's national task force for COVID-19 has decided against including antiviral drug Molnupiravir in the clinical management protocol for COVID-19 as of now, official sources said on Tuesday.

How Covid took devastating turn in 2021

How Covid took devastating turn in 2021

Rediff.com29 Dec 2021

A second wave of Covid driven by the Delta variant engulfed the country in May-June bringing the health system to its knees and leaving people gasping for help.

Only Covaxin available for 15-18-yr-olds, for now

Only Covaxin available for 15-18-yr-olds, for now

Rediff.com27 Dec 2021

Healthcare and frontline workers and citizens above 60 years of age with comorbidities would be administered the third dose of the same vaccine they had been given before.

Booster only after 9-12 months from 2nd jab: Experts

Booster only after 9-12 months from 2nd jab: Experts

Rediff.com26 Dec 2021

The gap between second dose of COVID-19 vaccine and the third, which is being called a 'precaution dose,' is likely to be nine to 12 months, official sources said on Sunday.

Covaxin gets nod for use in children above 12 years with riders

Covaxin gets nod for use in children above 12 years with riders

Rediff.com25 Dec 2021

The Subject Expert Committee on COVID-19 of the CDSCO on October 12 after deliberating Bharat Biotech's EUA application had recommended granting emergency use approval to Covaxin for use in the 12-18 years age group with certain conditions.

NTAGI mulls 'additional' Covid jab for immunocompromised

NTAGI mulls 'additional' Covid jab for immunocompromised

Rediff.com5 Dec 2021

According to officials, an additional dose of vaccine is different from a booster dose.

With over 30 mutations, Omicron may evade vaccines: Dr Guleria

With over 30 mutations, Omicron may evade vaccines: Dr Guleria

Rediff.com29 Nov 2021

The presence of spike protein facilitates a virus' entry into the host cell and is responsible for making it transmissible and causing infection.

Govt panel seeks additional data from SII on Covovax

Govt panel seeks additional data from SII on Covovax

Rediff.com28 Nov 2021

The Serum Institute of India (SII) had put in an application to the Drugs Controller General of India (DCGI) in October for grant of market authorisation of Covovax for restricted use in emergency situations.

Govt nod to commercial export of Covishield, Covaxin

Govt nod to commercial export of Covishield, Covaxin

Rediff.com25 Nov 2021

The quantity of Covid vaccines to be exported will be decided by the government every month to ensure there is no dearth of domestic availability.

Govt likely to allow post-mortem after sunset in certain hospitals

Govt likely to allow post-mortem after sunset in certain hospitals

Rediff.com15 Nov 2021

The aim is also to push for post-mortem for organ donation even after sundown if adequate infrastructure is available.

Made-in-India Covaxin gets WHO's emergency use licence

Made-in-India Covaxin gets WHO's emergency use licence

Rediff.com3 Nov 2021

Covaxin was found to have 78 per cent efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements, said the global health body.

Serum Institute seeks DCGI nod for Covovax

Serum Institute seeks DCGI nod for Covovax

Rediff.com29 Oct 2021

There were no safety concerns arising from the study data and Covovax is safe and immunogenic in the adult population, Prakash Kumar Singh, Director, Government and Regulatory Affairs at the Serum Institute of India (SII), is learnt to have said in the application sent to the DCGI.

Serum Institute seeks regular marketing approval for Covishield

Serum Institute seeks regular marketing approval for Covishield

Rediff.com25 Oct 2021

If the DCGI grants regular marketing authorisation, Covishied will be the second vaccine in the world to receive such approval.

Covaxin recommended by expert panel for 2-18 years

Covaxin recommended by expert panel for 2-18 years

Rediff.com12 Oct 2021

The Subject Expert Committee on COVID-19 examined the data and deliberated on the EUA application on Monday.

Next